A lipophilic AIEgen for lipid droplet imaging and evaluation of the efficacy of HIF-1 targeting drugs

被引:46
|
作者
Shi, Xiujuan [1 ,2 ,3 ]
Sung, Simon H. P. [1 ,2 ,3 ]
Lee, Michelle M. S. [2 ,3 ]
Kwok, Ryan T. K. [1 ,2 ,3 ]
Sung, Herman H. Y. [2 ,3 ]
Liu, Haixiang [1 ,2 ,3 ]
Lam, Jacky W. Y. [1 ,2 ,3 ]
Williams, Ian D. [2 ,3 ]
Liu, Bin [4 ]
Tang, Ben Zhong [1 ,2 ,3 ,5 ,6 ]
机构
[1] HKUST Shenzhen Res Inst, 9 Yuexing 1st RD,Hitech Pk, Shenzhen 518057, Peoples R China
[2] Hong Kong Univ Sci & Technol, Chinese Natl Engn Res Ctr Tissue Restorat & Recon, Dept Chem, Dept Chem & Biol Engn,Hong Kong Branch,Kowloon, Clear Water Bay, Hong Kong, Peoples R China
[3] Hong Kong Univ Sci & Technol, Inst Adv Study, Kowloon, Clear Water Bay, Hong Kong, Peoples R China
[4] Natl Univ Singapore, Dept Chem & Biomol Engn, Singapore 117585, Singapore
[5] Karolinska Inst, Ming Wai Lau Ctr Reparat Med, Hong Kong, Peoples R China
[6] South China Univ Technol, NSFC Ctr Luminescence Mol Aggregate, Guangdong Innovat Res Team, SCUT HKUST Joint Res Lab,State Key Lab Luminescen, Guangzhou 510640, Peoples R China
基金
美国国家科学基金会;
关键词
AGGREGATION-INDUCED EMISSION; INDUCIBLE FACTOR-I; FLUORESCENT-PROBE; LIVING CELLS; THERAPEUTIC TARGET; HYPOXIA; CANCER; INHIBITORS; ACID; HIF-1-ALPHA;
D O I
10.1039/c9tb02848j
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that mediates the cellular response to hypoxia. The upregulation of HIF-1 expression in hypoxic cells can induce the accumulation of lipid droplets (LDs), and the LD levels can in turn reflect the expression level of HIF-1. Herein, we report a LD-specific luminogen with aggregation-induced emission characteristics (AIEgen), and have explored its potential applications in the evaluation of the inhibitory efficacy of HIF-1 targeting drugs. Compared to Nile red, this AIEgen shows a larger Stokes shift, better photostability, a more sensitive response to changes in dye concentration and a broader quantitative range. We found that the AIEgen can be used for semi-quantifying LD levels in cancer cells under hypoxic conditions, and for evaluating the inhibitory efficacy of HIF-1 targeting drugs. This work provides a simple and cost-effective strategy for screening HIF-1-targeted drugs, which may also be an alternative for evaluating the drug efficacy of other LD-related diseases.
引用
收藏
页码:1516 / 1523
页数:8
相关论文
共 50 条
  • [31] miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1
    Zhou, Jianda
    Xu, Dan
    Xie, Huiqing
    Tang, Jingtian
    Liu, Rui
    Li, Jingjing
    Wang, Shaohua
    Chen, Xiang
    Su, Juan
    Zhou, Xiao
    Xia, Kun
    He, Quanyong
    Chen, Jia
    Xiong, Wei
    Cao, Peiguo
    Cao, Ke
    CANCER BIOLOGY & THERAPY, 2015, 16 (06) : 846 - 855
  • [32] An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor
    Shirai, Yukari
    Chow, Christalle C. T.
    Kambe, Gouki
    Suwa, Tatsuya
    Kobayashi, Minoru
    Takahashi, Itsuki
    Harada, Hiroshi
    Nam, Jin-Min
    CANCERS, 2021, 13 (11)
  • [33] A ruthenium(II) anthraquinone complex as the theranostic agent combining hypoxia imaging and HIF-1α inhibition
    Wang, Jinquan
    Kou, Junfeng
    Hou, Xiaojuan
    Zhao, Zizhuo
    Chao, Hui
    INORGANICA CHIMICA ACTA, 2017, 454 : 176 - 183
  • [34] HIF-1α and VEGF Immunophenotypes as Potential Biomarkers in the Prognosis and Evaluation of Treatment Efficacy of Atherosclerosis: A Systematic Review of the Literature
    Vageli, Dimitra P.
    Doukas, Panagiotis G.
    Georgiou, Dimitrios
    Prokopiou, Michailangelos P.
    Ladaki, Nefeli E.
    Papadopoulou, Androniki
    Doukas, Sotirios G.
    Zacharouli, Konstantina
    Makaritsis, Konstantinos P.
    Ioannou, Maria
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2025, 30 (01):
  • [35] CK1δ restrains lipin-1 induction, lipid droplet formation and cell proliferation under hypoxia by reducing HIF-1α/ARNT complex formation
    Kourti, Maria
    Ikonomou, Georgia
    Giakoumakis, Nikolaos-Nikiforos
    Rapsomaniki, Maria Anna
    Landegren, Ulf
    Siniossoglou, Symeon
    Lygerou, Zoi
    Simos, George
    Mylonis, Ilias
    CELLULAR SIGNALLING, 2015, 27 (06) : 1129 - 1140
  • [36] FV-429 enhances the efficacy of paclitaxel in NSCLC by reprogramming HIF-1α-modulated FattyAcid metabolism
    Guo, Yongjian
    Yang, Liliang
    Guo, Wenjing
    Wei, Libin
    Zhou, Yuxin
    CHEMICO-BIOLOGICAL INTERACTIONS, 2021, 350
  • [37] A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia
    Xu, Zichen
    Zhang, Bin
    Liao, Zhixin
    Gou, Shaohua
    BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 41
  • [38] Targeting HIF-1α Function in Cancer through the Chaperone Action of NQO1: Implications of Genetic Diversity of NQO1
    Salido, Eduardo
    Timson, David J.
    Betancor-Fernandez, Isabel
    Palomino-Morales, Rogelio
    Anoz-Carbonell, Ernesto
    Pacheco-Garcia, Juan Luis
    Medina, Milagros
    Pey, Angel L.
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (05):
  • [39] The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF
    Salva, Emine
    Turan, Suna Ozbas
    Eren, Fatih
    Akbuga, Julide
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 478 (01) : 147 - 154
  • [40] Liposomal PHD2 Inhibitors and the Enhanced Efficacy in Stabilizing HIF-1α
    Jian, Cheng-Bang
    Yu, Xu-En
    Gao, Hua-De
    Chen, Huai-An
    Jheng, Ren-Hua
    Chen, Chong-Yan
    Lee, Hsien-Ming
    NANOMATERIALS, 2022, 12 (01)